Investor Relations

Investor Kit
News Releases
Annual Report
Quarterly Reports
Events
Stock Information



News Releases

June 5, 2008
PDF Format
Pacgen Announces Positive Results from Phase IIb Dose-Ranging Trial of PAC-113
April 15, 2008
PDF Format
Pacgen Completes Patient Recruitment for Phase II Dose Ranging Trial of Novel Anti-Fungal Drug
March 17, 2008
PDF Format
Pacgen Closes $903,000 Private Placement Financing
February 29, 2008
PDF Format
Pacgen Reports Third Quarter Financial Results
November 28, 2007
PDF Format
Pacgen Reports Second Quarter Financial Results
November 19, 2007
PDF Format
Pacgen Initiates a Phase IIB Clinical Trial for PAC-113
November 13, 2007
PDF Format
Pacgen Presents Research Data at ACCP on Evaluation of a New Host Derived Synthetic Antifungal Peptide (PAC-113) in the Treatment of Oral Candidiasis
November 1, 2007
PDF Format
Pacgen to Present at the 9th Annual Acumen BioFin Rodman & Renshaw Healthcare Conference
October 10, 2007
PDF Format
Pacgen to Present at BIO InvestorForum 2007
October 3, 2007
PDF Format
Pacgen to Present at BioContact Quebec 2007
September 24, 2007
PDF Format
Pacgen Announces Advances in PAC-113 Program
August 28, 2007
PDF Format
Pacgen Reports Fiscal 2008 First Quarter Results
July 30, 2007
PDF Format
Pacgen Reports Fiscal 2007 Fourth Quarter Results
May 7, 2007
PDF Format
Pacgen Announces Positive Results from Phase I/II Trial of Novel Anti-Fungal Drug
listen to the Webcast
April 17, 2007
PDF Format
Pacgen to Present at BioFinance 2007
March 30, 2007
PDF Format
Pacgen Builds on New Leadership and Updates Options Outstanding
March 15, 2007
PDF Format
Pacgen Completes Patient Recruitment for Phase I/II Trial of Novel Anti-Fungal Drug
March 13, 2007
PDF Format
Pacgen Appoints Robert DuFresne as President & CEO
listen to the Webcast
March 1, 2007
PDF Format
Pacgen Reports Third Quarter Financial and Operating Results
February 12, 2007
PDF Format
Pacgen Appoints New Scientific Advisory Board Members
December 7, 2006
PDF Format
Pacgen Announces Closing of its Initial Public Offering
August 30, 2006
PDF Format
Pacgen Biopharmaceuticals Files for Initial Public Offering
July 17, 2006
PDF Format
Pacgen Biopharmaceuticals Names Dr. Alan Moore and Mr. Kevin McGarry to the Board of Directors
April 20, 2006
PDF Format
Pacgen Biopharmaceuticals Appoints Christina Yip as Chief Financial Officer
April 12, 2006
PDF Format
Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc.
March 7, 2006
PDF Format
Pacgen Biopharmaceuticals Receives Approval for Phase I/II Clinical Trial of PAC-113 for Oral Candidiasis
October 24, 2005
PDF Format
Pacgen Biopharmaceuticals Contracts Vancouver-based Syreon Corporation for its Phase I/II Clinical Trials of PAC-113 Mouthrinse in HIV Seropositive Patients with Oral Candidiasis
April 11, 2005
PDF Format
Pacgen Biopharmaceuticals Retains Dow Pharmaceutical Sciences for PAC-113 Phase I/II Human Clinical Trials
March 22, 2005
PDF Format
Pacgen Biopharmaceuticals In-Licenses Compounds for Oral Diseases from Demegen